Kozyreva Varvara K, Truong Chau-Linda, Greninger Alexander L, Crandall John, Mukhopadhyay Rituparna, Chaturvedi Vishnu
Microbial Diseases Laboratory, California Department of Public Health, Richmond, California, USA.
Microbial Diseases Laboratory, California Department of Public Health, Richmond, California, USA
J Clin Microbiol. 2017 Aug;55(8):2502-2520. doi: 10.1128/JCM.00361-17. Epub 2017 Jun 7.
Public health microbiology laboratories (PHLs) are on the cusp of unprecedented improvements in pathogen identification, antibiotic resistance detection, and outbreak investigation by using whole-genome sequencing (WGS). However, considerable challenges remain due to the lack of common standards. Here, we describe the validation of WGS on the Illumina platform for routine use in PHLs according to Clinical Laboratory Improvements Act (CLIA) guidelines for laboratory-developed tests (LDTs). We developed a validation panel comprising 10 isolates, 5 Gram-positive cocci, 5 Gram-negative nonfermenting species, 9 isolates, and 5 miscellaneous bacteria. The genome coverage range was 15.71× to 216.4× (average, 79.72×; median, 71.55×); the limit of detection (LOD) for single nucleotide polymorphisms (SNPs) was 60×. The accuracy, reproducibility, and repeatability of base calling were >99.9%. The accuracy of phylogenetic analysis was 100%. The specificity and sensitivity inferred from multilocus sequence typing (MLST) and genome-wide SNP-based phylogenetic assays were 100%. The following objectives were accomplished: (i) the establishment of the performance specifications for WGS applications in PHLs according to CLIA guidelines, (ii) the development of quality assurance and quality control measures, (iii) the development of a reporting format for end users with or without WGS expertise, (iv) the availability of a validation set of microorganisms, and (v) the creation of a modular template for the validation of WGS processes in PHLs. The validation panel, sequencing analytics, and raw sequences could facilitate multilaboratory comparisons of WGS data. Additionally, the WGS performance specifications and modular template are adaptable for the validation of other platforms and reagent kits.
公共卫生微生物学实验室(PHLs)正处于利用全基因组测序(WGS)在病原体鉴定、抗生素耐药性检测和疫情调查方面取得前所未有的进展的关键时刻。然而,由于缺乏通用标准,仍存在相当大的挑战。在此,我们根据临床实验室改进法案(CLIA)关于实验室自建检测方法(LDTs)的指南,描述了Illumina平台上WGS在PHLs常规使用中的验证情况。我们开发了一个验证面板,其中包括10株分离株,5株革兰氏阳性球菌、5株革兰氏阴性非发酵菌、9株分离株和5株其他细菌。基因组覆盖范围为15.71×至216.4×(平均为79.72×;中位数为71.55×);单核苷酸多态性(SNP)的检测限为60×。碱基识别的准确性、可重复性和重复性均>99.9%。系统发育分析的准确性为100%。从多位点序列分型(MLST)和基于全基因组SNP的系统发育分析推断的特异性和敏感性均为100%。完成了以下目标:(i)根据CLIA指南建立PHLs中WGS应用的性能规范,(ii)制定质量保证和质量控制措施,(iii)为有或没有WGS专业知识的最终用户开发报告格式,(iv)提供微生物验证集,以及(v)创建用于PHLs中WGS流程验证的模块化模板。验证面板、测序分析和原始序列有助于WGS数据的多实验室比较。此外,WGS性能规范和模块化模板适用于其他平台和试剂盒的验证。